Gallico L, Oggioni N, Dalla Rosa C, Ceserani R, Tognella S
Boehringer Mannheim Italia, Research Center, Monza, Italy.
Eur Respir J. 1996 Mar;9(3):478-85. doi: 10.1183/09031936.96.09030478.
Cough is a common symptom of respiratory diseases associated with irritation or inflammation of the airways, and symptomatic antitussive drugs are frequently prescribed to control an abnormal cough reflex. Our aim was to evaluate the effects of moguisteine, a novel, peripheral, nonnarcotic antitussive agent, on airway inflammation induced in guinea-pigs with a variety of stimuli. These stimuli included exposure to tobacco smoke for 10 min, to elicit airway hyperreactivity, eosinophil recruitment in bronchoalveolar lavage (BAL), airway epithelial damage and plasma exudation; graded platelet-activating factor (PAF) infusion (600 ng.kg-1 over one h), to induce airway hyperreactivity; 2% ovalbumin (OA) aerosol challenge in 1% OA-sensitized animals, to induce late-phase (17 and 72 h) airway leucocyte accumulation. We also assessed the activity of moguisteine on plasma leakage induced by capsaicin, on bronchoconstriction induced by acetylcholine (ACh), histamine (H) and PAF, and on leukotriene mediated allergic bronchospasm in OA-sensitized guinea-pig. Moguisteine (p.o. and i.m.) and dexamethasone (p.o. and i.m.) dose-dependently reduced tobacco smoke-induced bronchial hyperreactivity. Moguisteine and dexamethasone abolished eosinophil recruitment in BAL, prevented the sloughing of the epithelium and significantly reduced airway microvascular leakage. Both agents were also highly effective in reducing bronchial hyperreactivity elicited by PAF infusion. In addition, moguisteine was active in inhibiting airway neutrophil and eosinophil accumulation in BAL observed 17 and 72 h after OA challenge in sensitized guinea-pigs. In contrast to dexamethasone, moguisteine did not prevent capsaicin-induced plasma leakage. It was also ineffective against bronchoconstriction as induced by ACh, H, and PAF and failed to inhibit leukotriene-dependent bronchospasm. Our data suggest that moguisteine represents an antitussive compound endowed with interesting airway anti-inflammatory properties in guinea-pigs in vivo. Its mechanism of action remains to be elucidated.
咳嗽是与气道刺激或炎症相关的呼吸道疾病的常见症状,症状性镇咳药物经常被用于控制异常的咳嗽反射。我们的目的是评估一种新型外周非麻醉性镇咳药氨溴索对多种刺激物诱导的豚鼠气道炎症的影响。这些刺激物包括暴露于烟草烟雾10分钟,以引发气道高反应性、支气管肺泡灌洗(BAL)中嗜酸性粒细胞募集、气道上皮损伤和血浆渗出;分级输注血小板活化因子(PAF)(1小时内600 ng·kg-1),以诱导气道高反应性;在1%卵清蛋白(OA)致敏的动物中进行2% OA气雾剂激发,以诱导晚期(17和72小时)气道白细胞积聚。我们还评估了氨溴索对辣椒素诱导的血浆渗漏、乙酰胆碱(ACh)、组胺(H)和PAF诱导的支气管收缩以及OA致敏豚鼠中白三烯介导的过敏性支气管痉挛的作用。氨溴索(口服和肌肉注射)和地塞米松(口服和肌肉注射)剂量依赖性地降低了烟草烟雾诱导的支气管高反应性。氨溴索和地塞米松消除了BAL中的嗜酸性粒细胞募集,防止了上皮脱落,并显著减少了气道微血管渗漏。两种药物在降低PAF输注引起的支气管高反应性方面也非常有效。此外,氨溴索在抑制致敏豚鼠OA激发后17和72小时在BAL中观察到的气道中性粒细胞和嗜酸性粒细胞积聚方面具有活性。与地塞米松不同,氨溴索不能预防辣椒素诱导的血浆渗漏。它对ACh、H和PAF诱导的支气管收缩也无效,并且未能抑制白三烯依赖性支气管痉挛。我们的数据表明,氨溴索是一种在豚鼠体内具有有趣气道抗炎特性的镇咳化合物。其作用机制仍有待阐明。